As the result of a major breakthrough by researchers at Northwestern University’s School of Medicine, researchers studying amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s Disease, are now one step closer to unlocking the nature of ALS. The recent discovery, which for the first time identified a gene both in motor neurons in the brain and spinal cord affected by ALS, offers a glimpse of hope to those who currently suffer from the deadly disease which rapidly breaks down their bodies while leaving mental capacity intact.
Posts belonging to Category ALS Community News
This spirit of volunteerism also extends to our leadership. We have been fortunate to have some very bright and energetic people step forward to help plan how we might best serve the ALS community. With that in mind, we proudly announce that Melissa Marr has accepted the position of Marketing Director on the RASCALS Foundation Board of Directors.
We are a 100% all-volunteer 501(c)(3) non-profit charity. No one takes a paycheck here and there are no administrative costs. That means 100% of all funds raised by the R.A.S.C.A.L.S. Foundation go directly to fighting ALS.
The money goes to fund promising treatment research and development. It helps with ALS family assistance, such as our annual Higher Education Scholarship program.
Neuralstem ALS Trial Data Presented at the American Association of Neurological Surgeons Annual Meeting
“That our cells and method of delivery are safe in ALS patients bodes very well for expanding to other indications. We expect to commence our FDA-approved Phase I trial in chronic spinal cord injury later this year using the same methodology. We want to thank the surgeons at Emory, who developed these techniques, as well as the patients and their families who have taken part in the trial.”
April marks National Volunteer Month. This observance holds very special meaning for all of us here at the Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.). That’s because we are a 100% all-volunteer 501(c)(3) non-profit charity. There are no administrative costs.
That means no salaries, payments, or perks for anyone. Out-of-pocket expenses truly means out of our [...]
Antisense Oligonucleotides May be Feasible ALS Therapeutic Strategy
BOSTON, Massachusetts, March 29, 2013 — Published online today in Lancet Neurology, an SOD1-related familial ALS trial under the direction of NEALS researchers Timothy Miller, MD, PhD (Washington University School of Medicine) and Merit Cudkowicz (Massachusetts General Hospital) indicates that antisense oligonucleotide delivery to the central nervous system may [...]
TORONTO, Canada, March 20, 2013 /CNW/ — Amorfix Life Sciences announced today that it has furthered the development of the first effective blood test to diagnose amyotrophic lateral sclerosis (ALS) by cloning ultra-high affinity antibodies that detect a misfolded version of the enzyme superoxide dismutase 1 (SOD1), which has been implicated in the development of [...]
“This innovative diaphragm pacing system is an exciting development in the treatment of ALS. It has the potential to improve and extend the lives of hundreds of ALS patients. It is thrilling that our BWH team is able to bring this new treatment to ALS patients in New England,” said Dr. Ducko.
At a time when scientists are making rapid gains in the genetic roots of many diseases, Mr. Doctoroff, a former deputy mayor and private equity investor, is working with Mayor Michael R. Bloomberg and a private equity director, David M. Rubenstein, to put together a $25 million package of donations to support research to try to cure this rare and usually fatal degenerative neurological illness.
Long-time fans of the Allman Brothers were saddened to learn Feb. 27 that former guitarist Dan Toler died at the age of 65. Dan and his brother David “Frankie” Toler, a drummer, were involved with a number of bands over the years, including the Allman Brothers from 1979 to 1982. Contact Music shared the details [...]